LETTER TO THE EDITOR

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

Francesca Bizzaro1, Ilaria Fusco Nerini1,8, Molly A. Taylor2, Alessia Anastasia1, Massimo Russo1, Giovanna Damia3, Federica Guffanti3, Francesca Guana4, Paola Ostano4, Lucia Minoli5, Maureen M. Hattersley6, Stephanie Arnold2, Antonio Ramos-Montoya2, Stuart C. Williamson2, Alessandro Galbiati2, Jelena Urosevic2, Elisabetta Leo2, Ugo Cavallaro7, Carmen Ghilardi1, Simon T. Barry2†, Maria Rosa Bani1*† and Raffaella Giavazzi1†

Abstract
Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining PARP inhibition and VEGF-signalling, a cohort of patient-derived ovarian cancer xenografts (OC-PDXs), representative of the molecular characteristics and drug sensitivity of patient tumours, were treated with the PARPi olaparib and the VEGFR inhibitor cediranib at clinically relevant doses. The combination showed broad anti-tumour activity, reducing growth of all OC-PDXs, regardless of the homologous recombination repair (HRR) mutational status, with greater additive combination benefit in tumours poorly sensitive to platinum and olaparib. In orthotopic models, the combined treatment reduced tumour dissemination in the peritoneal cavity and prolonged survival. Enhanced combination benefit was independent of tumour cell expression of receptor tyrosine kinases targeted by cediranib, and not associated with change in expression of genes associated with DNA repair machinery. However, the combination of cediranib with olaparib was effective in reducing tumour vasculature in all the OC-PDXs. Collectively our data suggest that olaparib and cediranib act through complementary mechanisms affecting tumour cells and tumour microenvironment, respectively. This detailed analysis of the combined effect of VEGF-signalling and PARP inhibitors in OC-PDXs suggest that despite broad activity, there is no dominant common mechanistic inter-dependency driving therapeutic benefit.

Keywords: Ovarian cancer, Patient-derived xenograft, PARP inhibitor, VEGF pathway inhibitor, BRCA, Olaparib, Cediranib

To the Editor,
Olaparib is a first-in-class poly ADP-ribose polymerase inhibitor (PARPi) for treatment of recurrent platinum-responding ovarian cancer (OC) [1] with deleterious mutations in BRCA and other homologous recombination repair (HRR) pathway components which sensitize tumors to PARPi [2]. To increase the clinical therapeutic activity of PARPi, combination potential with vascular endothelial growth factor...
Our preclinical study assessed the benefit of combining VEGF signalling and PARP inhibition across a broad panel of patient-derived ovarian cancer xenografts (OC-PDXs). Cediranib potentiated the anti-tumor activity of olaparib regardless of the tumor's sensitivity to platinum and olaparib and BRCA1/2 mutational status.

A cohort of subcutaneous OC-PDXs representing diverse OC genotypes and phenotypes (Additional file 1: Figs. S1–S3) were treated with olaparib [1] and cediranib [5], mirroring clinical exposure [8]. Cediranib enhanced olaparib antitumor activity in all OC-PDXs, regardless of tumour histotype, HRR mutational status, expression of cediranib-targeted RTKs, sensitivity to platinum or olaparib monotherapy. As shown in Fig. 1A, the combination therapy showed broader activity versus olaparib monotherapy (81% vs 50%; \( P<0.0001 \); odds ratio of 3.9) across the OC-PDX panel, with greater antitumor benefit in tumours refractory to platinum and olaparib. Tumour control seen at 4 weeks (Fig. 1A) was maintained at 8 weeks (Additional file 1: Fig. S4) with no increased toxicity. Notably, the combination achieved a durable growth stabilization of the platinum/olaparib poorly responsive MNHOC182 and MNHOC18 tumours, which bear heterozygous mutations in \( BRCA2 \) (Fig. 1B and Additional file 1: Fig. S2). In \( BRCA \)-mutated and platinum/olaparib-sensitive OC-PDXs, the combination achieved rapid and prolonged tumour regression and this was evident also in tumours that no longer responded to olaparib at rechallenge (i.e. MNHOC513, MNHOC511, MNHOC508, Additional file 1: Fig. S6).

Extensive analysis was performed to identify potential drivers of combination efficacy. Consistent with its mode of action [9], cediranib dosed alone and in combination with olaparib significantly reduced OC-PDX tumour-associated vasculature (Fig. 1D and Additional file 1: Figs. S5, S7). Previous studies have suggested that cediranib-induced hypoxia sensitizes tumour cells to PARPi by reducing HRR gene expression [10], and that cediranib inhibits \( BRCA \) expression through platelet-derived growth factor receptor (PDGFR) inhibition, thus inducing a contextual tumour BRCaness [11]. Our analysis suggests that downregulation of HRR genes or modulation of PDGFR\( \beta \) signalling is not a dominant effect with respect to combination efficacy. A co-transplantation of subcutaneous OC-PDXs representing diverse OC genotypes and phenotypes (Additional file 1: Figs. S1–S3) were treated with olaparib [1] and cediranib [5], mirroring clinical exposure [8]. Cediranib enhanced olaparib antitumor activity in all OC-PDXs, regardless of tumour histotype, HRR mutational status, expression of cediranib-targeted RTKs, sensitivity to platinum or olaparib monotherapy. As shown in Fig. 1A, the combination therapy showed broader activity versus olaparib monotherapy (81% vs 50%; \( P<0.0001 \); odds ratio of 3.9) across the OC-PDX panel, with greater antitumor benefit in tumours refractory to platinum and olaparib. Tumour control seen at 4 weeks (Fig. 1A) was maintained at 8 weeks (Additional file 1: Fig. S4) with no increased toxicity. Notably, the combination achieved a durable growth stabilization of the platinum/olaparib poorly responsive MNHOC182 and MNHOC18 tumours, which bear heterozygous mutations in \( BRCA2 \) (Fig. 1B and Additional file 1: Fig. S2). In \( BRCA \)-mutated and platinum/olaparib-sensitive OC-PDXs, the combination achieved rapid and prolonged tumour regression and this was evident also in tumours that no longer responded to olaparib at rechallenge (i.e. MNHOC513, MNHOC511, MNHOC508, Additional file 1: Fig. S6).

Extensive analysis was performed to identify potential drivers of combination efficacy. Consistent with its mode of action [9], cediranib dosed alone and in combination with olaparib significantly reduced OC-PDX tumour-associated vasculature (Fig. 1D and Additional file 1: Figs. S5, S7). Previous studies have suggested that cediranib-induced hypoxia sensitizes tumour cells to PARPi by reducing HRR gene expression [10], and that cediranib inhibits \( BRCA \) expression through platelet-derived growth factor receptor (PDGFR) inhibition, thus inducing a contextual tumour BRCaness [11]. Our analysis suggests that downregulation of HRR genes or modification of PDGFR\( \beta \) signalling is not a dominant effect with respect to combination efficacy.
Fig. 1 (See legend on previous page.)
underpinning the combination benefit. Specifically, under severe hypoxic conditions in vitro, we did not observe any consistent change in RAD51 expression across a panel of OC cell lines (Additional file 1: Fig. S8). Moreover, downregulation of BRCA or RAD51 in vitro was only achieved at ≥ 3 μM concentrations of cediranib (Additional file 1: Fig. S9A,B), far higher than the clinical exposure. In contrast to other studies, BRCA or RAD51 modulation was not prevented by silencing of E2F4 (Additional file 1: Fig. S9B), the transcription factors suggested to regulate expression via PDGFRβ [11]. Consistent with this, HRR gene expression was not modulated in the OV2022 PDX by either short or long term dosing, despite increased combination benefit (Additional file 1: Fig. S10). Likewise in OC-PDXs, no common changes in the expression of a broad panel of genes (including HRR ones) by cediranib or the combination were found (Fig. 1C and Additional file 1: Figs. S5, S11), nor there was any association between RTK basal expression (Additional file 1: Fig. S3A) and sensitivity to treatments at the clinically relevant dose of cediranib (Figs. 1, 2). Indeed, cediranib addition to olaparib significantly impaired the growth of MNHOC182 tumors (Fig. 1B) which have low/null PDGFR expression (Fig. 1C). Pharmacokinetic modeling of the cediranib exposure profile in patients showed that robust inhibition of PDGFR is not achieved at clinically relevant doses [12] and consistent with our findings, olaparib efficacy is also enhanced by bevacizumab [2], which does not inhibit PDGFR, further supporting the conclusion that targeting PDGFR signalling is not a driver of combination benefit.

The benefit of the combination in controlling tumour progression was confirmed in three disease relevant orthotopic OC-PDXs (Fig. 2) that mimic human disease with dissemination occurring in the mouse peritoneal cavity [7]. Cediranib addition prolonged the lifespan of mice bearing the platinum/olaparib-responsive MNHOC8 (Fig. 2A) lacking BRCA1 expression (Additional file 1: Fig. S3) and most importantly the olaparib-resistant MNHOC506 and MNHOC22 (Fig. 2B, C). Analysis at 4 week of treatment, highlighted the need of both drugs controlling ascites formation and tumour dissemination (Fig. 2, right panels), resulting in survival increase. Tumour regrowth at therapy discontinuation (Additional file 1: Fig. S12) suggests that sustained treatment is required to maximise prolonged tumour control. Collectively these data suggest that PARPi and VEGFi target complementary mechanisms to reduce tumour and that continuous therapy may be clinically important to restrain tumour progression.

In summary, we show that the addition of cediranib enhances the antitumor efficacy of olaparib in both olaparib-sensitive and olaparib-resistant OCs. Preclinical activity was not associated with a mechanism priming response to cediranib or olaparib. Rather the agents appear to be complementary, with olaparib impacting DNA repair and cediranib modulating tumour vasculature, to increase response across the entire OC-PDXs panel. Our extensive experimental in vivo efficacy data reproduce clinical observations, while our comprehensive mechanistic analysis suggests the combination effect is largely driven by targeting independent mechanisms, rather than inducing specific changes that prime response to a partner drug.

(See figure on next page.)

**Fig. 2** Cediranib combined with olaparib reduces tumor dissemination and prolongs survival in orthotopic OC-PDXs. Drug effect in orthotopic OC-PDXs. Olaparib (100 mg/kg) and cediranib (3 mg/kg), monotherapy or combined, were given orally by gavage QD (Q1 × 5) until progression. **Left panels**: Survival (Kaplan Meier) curves of tumour bearing mice; the benefit calculated as increment of lifespan (ILS%) of disease bearing mice is indicated. Coloured bars at the bottom indicate the study dosing period. DDP response is reported in insert at the side. **Right panels**: Abdominal tumour burden (i.e. volume of ascites in the peritoneal cavity and organ dissemination) assessed after 4 weeks of treatment. Ascites and dissemination data are mean ± SD. “Random” indicates tumour burden at randomization (start of treatment). Statistic by Wilcoxon rank-sum test/log-rank test (left panels) or ANOVA and Tukey’s post-test (right panels). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001, *****P < 0.0001. A MNHOC8 (wild-type for BRCA genes Additional file 1: Fig. S1B but lacking BRCA1 mRNA due to promoter methylation Additional file 1: Fig. S3); mice were randomized 7 days after intraperitoneal tumor transplant. Vehicle N = 9, CED N = 12, OLA N = 12, OLA + CED N = 6. B MNHOC506 (wild-type for HRR genes; Additional file 1: Fig. S1B); mice were randomized 9 days after intraperitoneal tumor transplant. Vehicle N = 7, CED N = 7, OLA N = 7, OLA + CED N = 8. Representative images of tumor dissemination in liver are reported. C MNHOC22 (carrying a homozygous pathogenic nonsense mutation in BRCA1, truncating the protein; Additional file 1: Fig. S1B); mice were randomized 6 days after intraperitoneal tumor transplant. Vehicle N = 13, CED N = 9, OLA N = 13, OLA + CED N = 9. (Detailed methods in Additional file 2)
Fig. 2 (See legend on previous page.)
Abbreviations
CED. Cediranib; cKIT: KIT proto-oncogene, mast/stem cell growth factor receptor; DDP: Cis-diaminedichloroplatinum, cisplatin; HRD: Homologous recombination deficiency; HRR: Homologous recombination repair; IL-12: Immunohistochemistry; IPS: Increment of lifespan; OC: Ovarian cancer; OC-PDX: Patient-derived ovarian cancer xenograft; OLA: Olaparib; PARP: Poly ADP-ribose polymerase; PARPi: Poly ADP-ribose polymerase inhibitor; PDGFR: Platelet-derived growth factor receptor; PK: Pharmacokinetics; QD: quaque die, Once a day; RTK: Receptor tyrosine kinase; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045-021-01196-x.

Additional file 1. Supplementary Figure S1. Characteristics of the OC-PDXs used for drug efficacy testing. Supplementary Figure S2. Haploinsufficiency of the BRCA2 mutation in MNHOC182 and MNHOC18. Supplementary Figure S3. Transcriptional status of key genes in OC-PDXs and BRCA1 promoter methylation. Supplementary Figure S4. Antitumor activity of the olaparib and cediranib combination therapy at 8 weeks of treatment. Supplementary Figure S5. Cediranib reduced MNOC124 tumour associated vasculature but did not affect the expression of HRR genes. Supplementary Figure S6. Rapid and prolonged tumour response by the combination olaparib and cediranib in platinum-sensitive and olaparib-sensitive OC-PDXs. Supplementary Figure S7. Reduction of tumour associated vasculature by cediranib in the OC-PDXs cohort used for drug efficacy testing. Supplementary Figure S8. Hypoxia does not trigger the downregulation of HRR in ovarian cancer cell lines. Supplementary Figure S9. RADS1 downregulation is not related to PDGFRB pathway. Supplementary Figure S10. The combination olaparib and cediranib demonstrated greater efficacy than either monotherapy in OV2022 tumors: no therapy-induced changes in HRR genes could be detected. Supplementary Figure S11. No common changes in gene expression by cediranib treatment were identified in OC-PDXs that benefit from the combination therapy. Supplementary Figure S12. Survival advantage is lost upon treatment interruption. Supplementary Table S1. List of genes analysed by Fluidigm high-throughput gene expression analysis.

Additional file 2. Methods.

Acknowledgements
We thank Michela Lupia and Alessandra Decio for technical assistance, Luca Porcu for statistical analysis support and acknowledge Mark O’Connor, Gemma Jones, Maria Udriste and David Cochrane for their useful discussions and technical input.

Authors’ contributions
FB, STB, MRB, RG conceived and designed the study; FB, AA, SCW, ARM performed the in vivo studies; FB, MR sample preparations; MAT Fluidigm analysis; GD, FGuP promoter methylation PCR, LM, SA immunohistochemistry; AG in vitro studies; JU pharmacodynamic analysis on in vivo studies; FGua, PO analyzed RNAseq data, MWh designed and oversaw OV2022 studies; UC provided selected cell lines; EL input on DDR protein modulation studies; MRB, CG supervised the experimental work; IFN, STB, MRB, RG wrote the manuscript with input from all the authors. All authors read and approved the final manuscript.

Funding
Partially supported by AIRC IG 23520 to RG, AIRC IG 19797 to GD, AIRC IG21320 to UC.

Availability of data and materials
Data supporting the findings of this study are available within the article and Additional Files. The datasets generated during the current study are available from the corresponding author on reasonable request and with permission of AstraZeneca.

Declarations
Ethics approval and consent to participate
Animal studies were approved by the Mario Negri Institute Animal Care and Use Committee (IACUC) and authorised by the Italian Ministry of Health, Directorate-General for Animal Health and Veterinary Medicines. Experimental procedures involving mice and their care were conducted in conformity with institutional guidelines (Mario Negri Institutional Regulations and Policies - Quality Management System Certificate UNI EN ISO 9001:2008 Reg, No. 6121), in compliance with national and international laws and policies regulating animal testing (Italian D. Lgs 26/2014, EEC Council Directive 2010/63/UE).

Consent for publication
Not applicable.

Competing interests
MAT, MMH, SA, AR, SCW, AG, JU, EL, STB are AstraZeneca employees and shareholders. All other authors declare no competing interests.

Author details
1 Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy. 2 Early Oncology, AstraZeneca, Cambridge, UK. 3 Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 4 Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy. 5 Department of Veterinary Medicine, University of Milan, Milan, Italy. 6 Early Oncology, AstraZeneca, Boston, USA. 7 Unit of Gynecological Oncology Research, Istituto Europeo di Oncologia IRCCS, Milan, Italy. 8 Present Address: Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Received: 4 August 2021 Accepted: 18 October 2021
Published online: 06 November 2021

References
1. Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020. https://doi.org/10.1016/j.annonc.2020.06.004.
2. Ray-Coquard I, Pautier P, Pignata S, Pérold D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28. https://doi.org/10.1056/NEJMoa1911361.
3. Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer—standard of care for all? Nat Rev Clin Oncol. 2020;17:136–7. https://doi.org/10.1038/s41571-020-0335-9.
4. Arotta S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26:e164–72. https://doi.org/10.1002/1089-3107.a1911361.
5. Wedge SR, Kendrew J, Hennenquin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–400. https://doi.org/10.1158/0008-5472.CAN-04-4409.
6. Liu JF, Barry WT, Brirer M, Lee J-M, Buckanovich RJ, Fleming GF, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30:551–7. https://doi.org/10.1093/annonc/mdz018.
7. Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014;74:6980–90. https://doi.org/10.1158/0008-5472.CAN-14-0274.
8. Al-Huniti N, Peterson K, Tang W, Masson E, Li J. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with
9. Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184:1050–61. https://doi.org/10.1016/j.ajpath.2013.12.030.

10. Ivy SP, Liu JF, Lee J-M, Matulonis UA, Kohn EC. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016;25:597–611. https://doi.org/10.1517/13543784.2016.1156857.

11. Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aav4508.

12. Li J, Al-Huniti N, Henningsson A, Tang W, Masson E. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer. Br J Clin Pharmacol. 2017;83:1723–33. https://doi.org/10.1111/bcp.13266.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.